Amneal reports Q3 2026 revenue up 10% to $863M, adjusts full-year guidance higher amid new product launches.

Amneal Pharmaceuticals reported a 10% revenue increase in Q3 2026 to $863 million, driven by growth in biosimilars, women's health patches, and specialty products. Despite a GAAP net loss of $22 million due to acquisition and integration costs, adjusted EBITDA rose 30% to $207 million, and adjusted EPS increased 53% to $0.26. The company raised its full-year 2026 guidance for revenue, adjusted EBITDA, and adjusted EPS, citing strong performance and new product launches including biosimilars and injectables. Integration of the Kashiv acquisition is progressing well, supporting Amneal's confidence in long-term growth.

Amneal Pharmaceuticals' stock trades at USD 20.00 on Pluang as of Nov 03, 2026 18:02 WIB, near its 52-week high of USD 21.50 and well above its 52-week low of USD 11.20. Despite a 2.15% drop in one day, all Pluang orders are buys, reflecting strong investor interest. The stock's market cap stands at $7.49 billion, indicating solid market confidence amid the company's positive financial results.